Medtronic has received FDA marketing clearance for a portfolio of quadripolar cardiac resynchronization therapy-pacemakers (CRT-Ps) that improve therapy delivery for patients with heart failure.

The CRT-P portfolio received a CE mark in February 2017.

The Percepta Quad CRT-P MRI SureScan, Serena Quad CRT-P MRI SureScan and Solara Quad CRT-P MRI SureScan are expected to be available in the U.S. in early summer 2017. — Cynthia Jessup